Given the heterogeneous nature of breast cancer and its varying prognosis based on molecular profile, we stratified the cohort into three subgroups: HER2-positive (HER2+), hormone receptor-positive/HER2-negative (HR+), and triple-negative breast cancer (TN). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.